Cargando…

In silico analysis of binding interaction of conantokins with NMDA receptors for potential therapeutic use in Alzheimer’s disease

BACKGROUND: The N-methyl-D-aspartate (NMDA) receptors are glutamate receptors that play vital roles in central nervous system development and are involved in synaptic plasticity, which is an essential process for learning and memory. The subunit N-methyl D-aspartate receptor subtype 2B (NR2B) is the...

Descripción completa

Detalles Bibliográficos
Autores principales: Waqar, Maleeha, Batool, Sidra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607497/
https://www.ncbi.nlm.nih.gov/pubmed/28943883
http://dx.doi.org/10.1186/s40409-017-0132-9
_version_ 1783265297540579328
author Waqar, Maleeha
Batool, Sidra
author_facet Waqar, Maleeha
Batool, Sidra
author_sort Waqar, Maleeha
collection PubMed
description BACKGROUND: The N-methyl-D-aspartate (NMDA) receptors are glutamate receptors that play vital roles in central nervous system development and are involved in synaptic plasticity, which is an essential process for learning and memory. The subunit N-methyl D-aspartate receptor subtype 2B (NR2B) is the chief excitatory neurotransmitter receptor in the mammalian brain. Disturbances in the neurotransmission mediated by the NMDA receptor are caused by its overexposure to glutamate neurotransmitter and can be treated by its binding to an antagonist. Among several antagonists, conantokins from cone snails are reported to bind to NMDA receptors. METHODS: This study was designed to analyze the binding mode of conantokins with NMDA receptors in both humans and rats. To study interactions, dockings were performed using AutoDock 4.2 and their results were further analyzed using various computational tools. RESULTS: Detailed analyses revealed that these ligands can bind to active site residues of both receptors as reported in previous studies. CONCLUSIONS: In light of the present results, we suggest that these conantokins can act as antagonists of those receptors and play an important role in understanding the importance of inhibition of NMDA receptors for treatment of Alzheimer’s disease.
format Online
Article
Text
id pubmed-5607497
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56074972017-09-24 In silico analysis of binding interaction of conantokins with NMDA receptors for potential therapeutic use in Alzheimer’s disease Waqar, Maleeha Batool, Sidra J Venom Anim Toxins Incl Trop Dis Research BACKGROUND: The N-methyl-D-aspartate (NMDA) receptors are glutamate receptors that play vital roles in central nervous system development and are involved in synaptic plasticity, which is an essential process for learning and memory. The subunit N-methyl D-aspartate receptor subtype 2B (NR2B) is the chief excitatory neurotransmitter receptor in the mammalian brain. Disturbances in the neurotransmission mediated by the NMDA receptor are caused by its overexposure to glutamate neurotransmitter and can be treated by its binding to an antagonist. Among several antagonists, conantokins from cone snails are reported to bind to NMDA receptors. METHODS: This study was designed to analyze the binding mode of conantokins with NMDA receptors in both humans and rats. To study interactions, dockings were performed using AutoDock 4.2 and their results were further analyzed using various computational tools. RESULTS: Detailed analyses revealed that these ligands can bind to active site residues of both receptors as reported in previous studies. CONCLUSIONS: In light of the present results, we suggest that these conantokins can act as antagonists of those receptors and play an important role in understanding the importance of inhibition of NMDA receptors for treatment of Alzheimer’s disease. BioMed Central 2017-09-20 /pmc/articles/PMC5607497/ /pubmed/28943883 http://dx.doi.org/10.1186/s40409-017-0132-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Waqar, Maleeha
Batool, Sidra
In silico analysis of binding interaction of conantokins with NMDA receptors for potential therapeutic use in Alzheimer’s disease
title In silico analysis of binding interaction of conantokins with NMDA receptors for potential therapeutic use in Alzheimer’s disease
title_full In silico analysis of binding interaction of conantokins with NMDA receptors for potential therapeutic use in Alzheimer’s disease
title_fullStr In silico analysis of binding interaction of conantokins with NMDA receptors for potential therapeutic use in Alzheimer’s disease
title_full_unstemmed In silico analysis of binding interaction of conantokins with NMDA receptors for potential therapeutic use in Alzheimer’s disease
title_short In silico analysis of binding interaction of conantokins with NMDA receptors for potential therapeutic use in Alzheimer’s disease
title_sort in silico analysis of binding interaction of conantokins with nmda receptors for potential therapeutic use in alzheimer’s disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607497/
https://www.ncbi.nlm.nih.gov/pubmed/28943883
http://dx.doi.org/10.1186/s40409-017-0132-9
work_keys_str_mv AT waqarmaleeha insilicoanalysisofbindinginteractionofconantokinswithnmdareceptorsforpotentialtherapeuticuseinalzheimersdisease
AT batoolsidra insilicoanalysisofbindinginteractionofconantokinswithnmdareceptorsforpotentialtherapeuticuseinalzheimersdisease